$OSUR
OraSure Technologies Inc

2015 Q1 Form 10-Q Financial Statement

#000119312515179570 Filed on May 08, 2015

View on sec.gov

Income Statement

Concept 2015 Q1 2014 Q1
Revenue $27.09M $23.54M
YoY Change 15.09% 11.21%
Cost Of Revenue $10.09M $9.610M
YoY Change 4.99% 5.2%
Gross Profit $17.00M $13.93M
YoY Change 22.05% 15.78%
Gross Profit Margin 62.75% 59.17%
Selling, General & Admin $13.85M $17.06M
YoY Change -18.84% -11.41%
% of Gross Profit 81.47% 122.52%
Research & Development $3.440M $2.481M
YoY Change 38.65% -26.09%
% of Gross Profit 20.24% 17.81%
Depreciation & Amortization $1.409M $1.539M
YoY Change -8.45% -3.93%
% of Gross Profit 8.29% 11.05%
Operating Expenses $17.29M $19.55M
YoY Change -11.54% -13.59%
Operating Profit -$291.0K -$5.618M
YoY Change -94.82% -46.94%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $409.0K $118.0K
YoY Change 246.61% -351.06%
Pretax Income $118.0K -$5.500M
YoY Change -102.15% -48.29%
Income Tax $5.000K $131.0K
% Of Pretax Income 4.24%
Net Earnings $113.0K -$5.631M
YoY Change -102.01% -44.93%
Net Earnings / Revenue 0.42% -23.92%
Basic Earnings Per Share $0.00 -$0.10
Diluted Earnings Per Share $0.00 -$0.10
COMMON SHARES
Basic Shares Outstanding 56.34M shares 55.76M shares
Diluted Shares Outstanding 57.17M shares 55.76M shares

Balance Sheet

Concept 2015 Q1 2014 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $89.50M $84.20M
YoY Change 6.29% 6.18%
Cash & Equivalents $85.55M $84.19M
Short-Term Investments $3.900M
Other Short-Term Assets $149.0K $197.0K
YoY Change -24.37% -94.53%
Inventory $15.62M $11.99M
Prepaid Expenses
Receivables $16.37M $13.29M
Other Receivables $0.00 $0.00
Total Short-Term Assets $123.2M $111.8M
YoY Change 10.23% -1.01%
LONG-TERM ASSETS
Property, Plant & Equipment $17.65M $17.83M
YoY Change -1.02% -2.59%
Goodwill $19.91M $22.86M
YoY Change -12.89%
Intangibles $15.58M $20.66M
YoY Change -24.58%
Long-Term Investments
YoY Change
Other Assets $1.320M $980.0K
YoY Change 34.69% 226.67%
Total Long-Term Assets $54.46M $62.33M
YoY Change -12.62% -9.8%
TOTAL ASSETS
Total Short-Term Assets $123.2M $111.8M
Total Long-Term Assets $54.46M $62.33M
Total Assets $177.6M $174.1M
YoY Change 2.05% -4.35%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.037M $4.114M
YoY Change 22.44% -26.54%
Accrued Expenses $6.877M $9.902M
YoY Change -30.55% 45.62%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $17.53M $14.97M
YoY Change 17.13% -16.83%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.311M $961.0K
YoY Change 36.42% 380.5%
Total Long-Term Liabilities $1.311M $961.0K
YoY Change 36.42% 380.5%
TOTAL LIABILITIES
Total Short-Term Liabilities $17.53M $14.97M
Total Long-Term Liabilities $1.311M $961.0K
Total Liabilities $18.85M $15.93M
YoY Change 18.29% -27.91%
SHAREHOLDERS EQUITY
Retained Earnings -$178.2M -$179.4M
YoY Change -0.63%
Common Stock $345.7M $339.7M
YoY Change 1.79%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $155.8M $154.7M
YoY Change
Total Liabilities & Shareholders Equity $177.6M $174.1M
YoY Change 2.05% -4.35%

Cashflow Statement

Concept 2015 Q1 2014 Q1
OPERATING ACTIVITIES
Net Income $113.0K -$5.631M
YoY Change -102.01% -44.93%
Depreciation, Depletion And Amortization $1.409M $1.539M
YoY Change -8.45% -3.93%
Cash From Operating Activities -$6.590M -$7.670M
YoY Change -14.08% 0.0%
INVESTING ACTIVITIES
Capital Expenditures $437.0K $647.0K
YoY Change -32.46% 34.79%
Acquisitions
YoY Change
Other Investing Activities $1.040M
YoY Change
Cash From Investing Activities $600.0K -$650.0K
YoY Change -192.31% 35.42%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $772.0K $521.0K
YoY Change 48.18% -29.88%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -650.0K -430.0K
YoY Change 51.16% -2.27%
NET CHANGE
Cash From Operating Activities -6.590M -7.670M
Cash From Investing Activities 600.0K -650.0K
Cash From Financing Activities -650.0K -430.0K
Net Change In Cash -6.640M -8.750M
YoY Change -24.11% 1.86%
FREE CASH FLOW
Cash From Operating Activities -$6.590M -$7.670M
Capital Expenditures $437.0K $647.0K
Free Cash Flow -$7.027M -$8.317M
YoY Change -15.51% 2.05%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
56417001 shares
CY2014Q1 us-gaap Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
1778000
CY2014Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
84193000
CY2015Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.000001
CY2015Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
345718000
CY2015Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1514000
CY2015Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2902000
CY2015Q1 us-gaap Stockholders Equity
StockholdersEquity
155827000
CY2015Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1311000
CY2015Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
758000
CY2015Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
16201000
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6369000 shares
CY2015Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000 shares
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
696000 shares
CY2015Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
56416000 shares
CY2015Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.000001
CY2015Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000 shares
CY2015Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2015Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
56416000 shares
CY2015Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
5492000
CY2015Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
5037000
CY2015Q1 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
543000
CY2015Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6877000
CY2015Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-178232000
CY2015Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
177642000
CY2015Q1 us-gaap Common Stock Value
CommonStockValue
0
CY2015Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q1 us-gaap Deferred Tax Liabilities Current
DeferredTaxLiabilitiesCurrent
128000
CY2015Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
32049000
CY2015Q1 us-gaap Liabilities Current
LiabilitiesCurrent
17534000
CY2015Q1 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
1703000
CY2015Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2015Q1 us-gaap Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
3811000
CY2015Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-11659000
CY2015Q1 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
2970000
CY2015Q1 us-gaap Inventory Raw Materials
InventoryRawMaterials
8256000
CY2015Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1320000
CY2015Q1 us-gaap Assets
Assets
177642000
CY2015Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
15581000
CY2015Q1 us-gaap Inventory Net
InventoryNet
15619000
CY2015Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
16367000
CY2015Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
17645000
CY2015Q1 us-gaap Deferred Compensation Plan Assets
DeferredCompensationPlanAssets
1314000
CY2015Q1 us-gaap Assets Current
AssetsCurrent
123183000
CY2015Q1 us-gaap Other Assets Current
OtherAssetsCurrent
149000
CY2015Q1 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
31782000
CY2015Q1 us-gaap Inventory Finished Goods
InventoryFinishedGoods
6599000
CY2015Q1 us-gaap Goodwill
Goodwill
19913000
CY2015Q1 us-gaap Inventory Work In Process
InventoryWorkInProcess
764000
CY2015Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1559000
CY2015Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
85547000
CY2015Q1 us-gaap Short Term Investments
ShortTermInvestments
3942000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
93191000
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5740000 shares
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000 shares
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
707000 shares
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
56187000 shares
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.000001
CY2014Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000 shares
CY2014Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
56187000 shares
CY2014Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.000001
CY2014Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
344894000
CY2014Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1747000
CY2014Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6620000
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
158701000
CY2014Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1234000
CY2014Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
480000
CY2014Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
16227000
CY2014Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
8043000
CY2014Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
7148000
CY2014Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
533000
CY2014Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
11132000
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-178345000
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
189633000
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
0
CY2014Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q4 us-gaap Deferred Tax Liabilities Current
DeferredTaxLiabilitiesCurrent
139000
CY2014Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
31416000
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
26462000
CY2014Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
2285000
CY2014Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2014Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-7848000
CY2014Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
3236000
CY2014Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
8539000
CY2014Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1246000
CY2014Q4 us-gaap Assets
Assets
189633000
CY2014Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
17505000
CY2014Q4 us-gaap Inventory Net
InventoryNet
15763000
CY2014Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
16138000
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
17934000
CY2014Q4 us-gaap Deferred Compensation Plan Assets
DeferredCompensationPlanAssets
1234000
CY2014Q4 us-gaap Assets Current
AssetsCurrent
131214000
CY2014Q4 us-gaap Other Assets Current
OtherAssetsCurrent
306000
CY2014Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
33732000
CY2014Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
6326000
CY2014Q4 us-gaap Goodwill
Goodwill
21734000
CY2014Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
898000
CY2014Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1140000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
92867000
CY2014Q4 us-gaap Short Term Investments
ShortTermInvestments
5000000
CY2014 us-gaap Concentration Risk Percentage1
ConcentrationRiskPercentage1
0.10 pure
CY2014 us-gaap Revenue Recognition Sales Returns Reserve For Sales Returns
RevenueRecognitionSalesReturnsReserveForSalesReturns
437000
CY2014Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.10
CY2014Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-7668000
CY2014Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3698000 shares
CY2014Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
55762000 shares
CY2014Q1 us-gaap Concentration Risk Percentage1
ConcentrationRiskPercentage1
0.10 pure
CY2014Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
55762000 shares
CY2014Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.10
CY2014Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
647000
CY2014Q1 us-gaap Net Income Loss
NetIncomeLoss
-5631000
CY2014Q1 us-gaap Revenues
Revenues
23537000
CY2014Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
280000
CY2014Q1 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
521000
CY2014Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-5618000
CY2014Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
586000
CY2014Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
40000
CY2014Q1 us-gaap Gross Profit
GrossProfit
13927000
CY2014Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
118000
CY2014Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
402000
CY2014Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-1778000
CY2014Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7409000
CY2014Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1778000
CY2014Q1 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
23537000
CY2014Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-5500000
CY2014Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1406000
CY2014Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-153000
CY2014Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
11340000
CY2014Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-8998000
CY2014Q1 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
131000
CY2014Q1 us-gaap Operating Expenses
OperatingExpenses
19545000
CY2014Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-647000
CY2014Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-428000
CY2014Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2481000
CY2014Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
131000
CY2014Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-3009000
CY2014Q1 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
0
CY2014Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
93000
CY2014Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5724000
CY2014Q1 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-255000
CY2014Q1 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0
CY2014Q1 us-gaap Cost Of Goods Sold
CostOfGoodsSold
9610000
CY2014Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-683000
CY2014Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1539000
CY2014Q1 us-gaap Deferred Tax Expense From Stock Options Exercised
DeferredTaxExpenseFromStockOptionsExercised
0
CY2015Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2015Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.00
CY2015Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-6591000
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
35000 shares
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
265000 shares
CY2015Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2015
CY2015Q1 dei Amendment Flag
AmendmentFlag
false
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
29000 shares
CY2015Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2702000 shares
CY2015Q1 dei Document Type
DocumentType
10-Q
CY2015Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001116463
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
9000 shares
CY2015Q1 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2015Q1 us-gaap Revenue Recognition Deferred Revenue
RevenueRecognitionDeferredRevenue
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> <i><u>Deferred Revenue</u>.</i> We record deferred revenue when funds are received prior to the recognition of the associated revenue. Deferred revenue as of March&#xA0;31, 2015 and December&#xA0;31, 2014 includes customer prepayments of $1,386 and $613, respectively. Deferred revenue as of March&#xA0;31, 2015 and December&#xA0;31, 2014 also includes $4,106 and $7,430 from AbbVie, respectively, which represents the $15,000 payment received in July 2014 under the terms of our HCV co-promotion agreement with AbbVie, less amounts recognized ratably in revenue.</p> </div>
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
267000 shares
CY2015Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2015Q1 dei Entity Registrant Name
EntityRegistrantName
ORASURE TECHNOLOGIES INC
CY2015Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
57173000 shares
CY2015Q1 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
830000 shares
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
767000 shares
CY2015Q1 us-gaap Revenue Recognition Sales Returns
RevenueRecognitionSalesReturns
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> <i><u>Customer Sales Returns and Allowances</u>.</i> We do not grant return rights to our customers for any product, except for our OraQuick<sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top">&#xAE;</sup> In-Home HIV test. Accordingly, we have recorded an estimate of expected returns as a reduction of gross OraQuick<sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top">&#xAE;</sup> In-Home HIV product revenues in our consolidated statements of operations. This estimate reflects our historical sales experience to retailers and consumers, as well as other retail factors, and is reviewed regularly to ensure that it reflects potential product returns. As of March&#xA0;31, 2015 and December&#xA0;31, 2014, the reserve for sales returns and allowances was $387 and $437, respectively. If actual product returns differ materially from our reserve amount, or if a determination is made that this product&#x2019;s distribution would be discontinued in whole or in part by certain retailers, then we would need to adjust our reserve. Should the actual level of product returns vary significantly from our estimates, our operating and financial results could be materially affected.</p> </div>
CY2015Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
56343000 shares
CY2015Q1 dei Document Period End Date
DocumentPeriodEndDate
2015-03-31
CY2015Q1 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> <i><u>Use of Estimates</u>.</i> The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions about future events. These estimates and underlying assumptions affect the amounts of assets and liabilities reported, disclosures about contingent assets and liabilities, and reported amounts of revenues and expenses. Such estimates include the valuation of accounts receivable and inventories and assumptions utilized in impairment testing for intangible assets and goodwill, as well as calculations related to contingencies and accruals, among others. These estimates and assumptions are based on management&#x2019;s best estimates and judgment. Management evaluates its estimates and assumptions on an ongoing basis, using historical experience and other factors which management believes to be reasonable under the circumstances, including the current economic environment. We adjust such estimates and assumptions when facts and circumstances dictate. Illiquid credit markets, volatile equity and foreign currency markets, reductions in government funding, and declines in consumer spending have combined to increase the uncertainty inherent in such estimates and assumptions. As future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Changes in those estimates resulting from continuing changes in the economic environment and other factors will be reflected in the financial statements in those future periods.</p> </div>
CY2015Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
74000 shares
CY2015Q1 dei Trading Symbol
TradingSymbol
OSUR
CY2015Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.00
CY2015Q1 us-gaap Revenue Recognition Milestone Method Milestone
RevenueRecognitionMilestoneMethodMilestone
We may be eligible to receive additional milestone payments. These payments would be based upon the aggregate number of new patients enrolled in the patient care database, in a given calendar year, after exceeding a baseline threshold, and could range from $3,500 to $55,500 annually over the term of the agreement. The first performance-based milestone period ends on December 31, 2015.
CY2015Q1 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2 Segment
CY2015Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
437000
CY2015Q1 us-gaap Net Income Loss
NetIncomeLoss
113000
CY2015Q1 us-gaap Revenues
Revenues
27088000
CY2015Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
290000
CY2015Q1 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
772000
CY2015Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-291000
CY2015Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-57000
CY2015Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
81000
CY2015Q1 us-gaap Gross Profit
GrossProfit
16998000
CY2015Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
409000
CY2015Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
552000
CY2015Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-3811000
CY2015Q1 us-gaap Payments For Proceeds From Short Term Investments
PaymentsForProceedsFromShortTermInvestments
-5000000
CY2015Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
118000
CY2015Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1475000
CY2015Q1 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
3961000
CY2015Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3698000
CY2015Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-3811000
CY2015Q1 us-gaap Revenue Recognition Sales Returns Reserve For Sales Returns
RevenueRecognitionSalesReturnsReserveForSalesReturns
387000
CY2015Q1 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
23765000
CY2015Q1 us-gaap Other Sales Revenue Net
OtherSalesRevenueNet
3323000
CY2015Q1 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
71000
CY2015Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-2542000
CY2015Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
7884000
CY2015Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-7320000
CY2015Q1 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
5000
CY2015Q1 us-gaap Operating Expenses
OperatingExpenses
17289000
CY2015Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
602000
CY2015Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-651000
CY2015Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3440000
CY2015Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
5000
CY2015Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-4133000
CY2015Q1 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
0
CY2015Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
121000
CY2015Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5965000
CY2015Q1 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-680000
CY2015Q1 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0
CY2015Q1 us-gaap Cost Of Goods Sold
CostOfGoodsSold
10090000
CY2015Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2062000
CY2015Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1409000
CY2015Q1 us-gaap Deferred Tax Expense From Stock Options Exercised
DeferredTaxExpenseFromStockOptionsExercised
0
CY2015Q1 osur Rights Agreement Expiration Date
RightsAgreementExpirationDate
2019-12-31

Files In Submission

Name View Source Status
0001193125-15-179570-index-headers.html Edgar Link pending
0001193125-15-179570-index.html Edgar Link pending
0001193125-15-179570.txt Edgar Link pending
0001193125-15-179570-xbrl.zip Edgar Link pending
d913408d10q.htm Edgar Link pending
d913408dex311.htm Edgar Link pending
d913408dex312.htm Edgar Link pending
d913408dex321.htm Edgar Link pending
d913408dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
osur-20150331.xml Edgar Link completed
osur-20150331.xsd Edgar Link pending
osur-20150331_cal.xml Edgar Link unprocessable
osur-20150331_def.xml Edgar Link unprocessable
osur-20150331_lab.xml Edgar Link unprocessable
osur-20150331_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending